Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic Anemia

Eltrombopag increases hematologic response in patients with treatment-naïve severe aplastic anemiaПодробнее

Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic AnemiaПодробнее

The Role of Supportive Care in Severe Aplastic AnemiaПодробнее

RACE: evaluating eltrombopag in severe aplastic anemiaПодробнее

Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic AnemiaПодробнее

Frontline Shift for Severe Aplastic Anemia After Eltrombopag FDA ApprovalПодробнее

Exciting new immunosuppressive therapy treatment for aplastic anaemiaПодробнее

Advances in transplantation and drug treatments for idiopathic aplastic anemiaПодробнее

Upcoming SAA research: cyclosporine and eltrombopagПодробнее

Impact of Eltrombopag in Refractory Aplastic AnemiaПодробнее

Danielle M. TownsleyПодробнее

Eltrombopag in a nutshell - Promacta (Pronunciation - Indication - US Black Box)Подробнее

A two-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemiaПодробнее

Conversations with Innovators: Neal Young, MDПодробнее

Eltrombopag for aplastic anaemia in EuropeПодробнее

Webinar: Moderate, Severe, Very Severe Aplastic Anemia 2018Подробнее

Aplastic anemia updates: RACE, the role of anabolic steroids, clonal architecture & moreПодробнее

Unmet Needs in Severe Aplastic Anemia and Exciting Ongoing DevelopmentsПодробнее

ASH 2016: Aplastic Anemia Research UpdateПодробнее